Barnieh, L, Manns, B, Harris, A, et al.
A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries. Value Health. 2014;17:98-108.
Tugwell, P, Knottnerus, JA. Is the ‘Evidence-Pyramid’ now dead?
J Clin Epidemiol. 2015;68:1247-1250.
Malmstrom, RE, Godman, BB, Diogene, E, et al.
Dabigatran - A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
Gold, R, Kappos, L, Arnold, DL, et al.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107.
Joppi, R, Cinconze, E, Mezzalira, L, et al.
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study. Eur J Intern Med. 2013;24:318-323.
Divittorio, G, Jackson, KL, Chindalore, VL, Welker, W, Walker, JB. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy. 2006;26:104-114.
Prasad, V, Kim, C, Burotto, M, Vandross, A. The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175:1389-1398.
Svensson, S, Menkes, DB, Lexchin, J. Surrogate outcomes in clinical trials: A cautionary tale. JAMA Intern Med. 2013;173:611-612.
Henshall, C, Sansom, L, Eichler, H-G, et al.
Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require?
Ther Innov Regul Sci. 2014;48:341-346.
Downing, NS, Aminawung, JA, Shah, ND, Krumholz, HM, Ross, JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA. 2014;311:368-377.
Avorn, J, Kesselheim, AS. The 21st Century Cures Act–Will it take us back in time?
N Engl J Med. 2015;372:2473-2475.
Anderson, ML, Chiswell, K, Peterson, ED, Tasneem, A, Topping, J, Califf, RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med.
Gafni, A, Birch, S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med. 2006;62:2091-2100.
McCabe, C, Claxton, K, Culyer, AJ. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics. 2008;26:733-744.
Howard, DH, Bach, P, Berndt, ER, Conti, RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139-162.
Simoens, S, Picavet, E, Dooms, M, Cassiman, D, Morel, T. Cost-effectiveness assessment of orphan drugs: A scientific and political conundrum. Appl Health Econ Health Policy. 2013;11:1-3.
NICE's cost-effectiveness range: Should it be lowered?
Ferrario, A, Kanavos, P. Managed entry agreements for pharmaceuticals: The European experience. London School of Economics and Political Science. 2013;154. http://eprints.lse.ac.uk/50513/ (accessed November 1, 2016).
Caires de Souza, AL, de Assis Acurcio, F, Guerra Junior, AA, Rezende Macedo do Nascimento, RC, Godman, B, Diniz, LM. Insulin glargine in a Brazilian state: Should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12: 19-32.
Gomes, RM, Guerra Júnior, AA, Lemos, LL, et al.
Tenyear kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016;9:991-999.
Raaschou, P, Simard, JF, Holmqvist, M, Askling, J, Group, AS. Rheumatoid arthritis, antitumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.
de Oliveira Costa, J, Almeida-Brasil, CC, Godman, B, et al.
Implementation of clinical guidelines in Brazil: Should academic detailing be used?
Daniels, T, Williams, I, Robinson, S, Spence, K. Tackling disinvestment in health care services. The views of resource allocators in the English NHS. J Health Organ Manag. 2013;27:762-780.
Frønsdal, KB, Facey, K, Klemp, M, Norderhaug, IN, Mørland, B, Røttingen, JA. Health technology assessment to optimize health technology utilization: Using implementation initiatives and monitoring processes. Int J Technol Assess Health Care. 2010;26:309-316.
Elshaug, AG, Moss, JR, Littlejohns, P, Karnon, J, Merlin, TL, Hiller, JE. Identifying existing health care services that do not provide value for money. Med J Aust. 2009;190:269-273.
Husereau, D, Boucher, M, Noorani, H. Priority setting for health technology assessment at CADTH. Int J Technol Assess Health Care. 2010;26:341-347.
Parkinson, B, Sermet, C, Clement, F, et al.
Disinvestment and value-based purchasing strategies for pharmaceuticals: An international review. Pharmacoeconomics. 2015;33:905-924.
Ford, I, Murray, H, McCowan, C, Packard, CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133:1073-1080